Checks bypass graft openness in heart attack patients after surgery on two blood-thinner plans
Compares graft openness with aspirin alone versus aspirin plus ticagrelor in adults after bypass surgery.
Plain-language title generated from the registry record
Registry title: Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)
Key facts
- Where
- Gothenburg, Linköping, Örebro, and Stockholm, SwedenSee the 4 sites
Where in Sweden
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of MedicineGothenburg, SwedenEnrolling by invitation
- University Hospital LinköpingLinköping, SwedenTaking people
- Dep of Vascular and Thoracic SurgeryÖrebro, SwedenNo longer taking part
- Department of Cardiothoracic Surgery Karolinska University HospitalStockholm, SwedenEnrolling by invitation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Linkoeping
- Trial code
- NCT04783701
- Record updated
- 19 December 2025
- Original description
The purpose of this study is to compare the presence of graft patency in single aspirin vs dual anti platelet therapy (DAPT) treatment including ticagrelor in patients with acute coronary syndrome (ACS) treated with coronary artery bypass surgery (CABG). Follow up time is 12-36 months postoperatively and the patency will be evaluated with coronary computed tomography angiography (CCTA)Read full original descriptionShow less
Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)
The purpose of this study is to compare the presence of graft patency in single aspirin vs dual anti platelet therapy (DAPT) treatment including ticagrelor in patients with acute coronary syndrome (ACS) treated with coronary artery bypass surgery (CABG). Follow up time is 12-36 months postoperatively and the patency will be evaluated with coronary computed tomography angiography (CCTA)
Inclusion: Previously included in TACSI-trial.
Exclusion: Previous severe allergic reaction (i.e. anaphylactic reaction) to iodine-based contrast agents; Highly irregular heart rhythm (i.e. atrial fibrillation); Chronic kidney disease with estimated glomerular filtration rate (eGFR) <45ml/min/1,73m2; Body weight >120 kg; Not able to communicate; Not willing to participate.